1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Expanded Access: FDA To Clarify How Adverse Events Impact Drug Approval Process

 
• By Brenda Sandburg

GAO says lack of clear information from FDA may influence whether manufacturers grant expanded access to investigational drugs; only two clinical holds have been due to adverse events from expanded access use.

FDAEntrance_1200x675

The US Government Accountability Office (GAO) had only one recommendation for FDA after reviewing its expanded access program: the agency should clearly communicate how it uses adverse events data from the program in reviewing a drug for approval.

In a recent report, GAO said some manufacturers and other stakeholders contend that FDA is not clear about...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

Hope For Stability, Credibility As US FDA Vet Pazdur Takes Over CDER

 
• By Sarah Karlin-Smith

The appointment of longtime FDA oncology leader Richard Pazdur to lead FDA's Center for Drug Evaluation and Research is being well received.

Makary’s Expert Panel Sparks Regulatory Action For Menopause Hormonal Therapy

 
• By Sarah Karlin-Smith

The requested changes to the class-wide warnings for hormone replacement therapies mark the first time one of Makary’s expert panels sparked regulatory action and could lead to broader scrutiny of their use.

Proposed Shutdown-Ending Agreement Would Cut US FDA Non-User Fee Funding

 
• By Derrick Gingery

But the Senate’s reduction would not be as much as the House of Representatives and President Trump proposed earlier this year, which is likely a win for the agency.

US FDA ANDA Priority Pilot ‘Practically Unusable’ Without Tweaks, AAM CEO Says

 
• By Sarah Karlin-Smith

Association for Accessible Medicines CEO John Murphy told the Pink Sheet that the FDA may need to consider phasing in the requirements for the new ANDA priority voucher incentive program if it wants sponsors to apply in the near-term.

More from Agency Leadership

Pink Sheet Podcast: Examining George Tidmarsh’s Departure As Head Of US FDA’s Drug Center

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors explain Tidmarsh’s abrupt resignation as the FDA’s chief drug regulator and the potential impact on the already reeling agency.

FDA Office of New Drugs Director Mary Thanh Hai Not Interested In CDER Director Job

 
• By Sue Sutter

The 27-year agency veteran has not been formally approached about filling the vacancy created by George Tidmarsh’s resignation, but also is not interested in the position, the Pink Sheet has learned.

Former US FDA Employee Severance Suspended Due To Government Shutdown

 
• By Sue Sutter

Employees subject to the April 1 reduction-in-force began noticing severance payments had been stopped the week of Nov. 3, before the FDA Office of Human Capital Management announced the suspension of all payments to former staffers due to the lapse in appropriations.